Pharmacological treatment of the biochemical defect in cystic fibrosis airways.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  European Respiratory Journal

• Publication date

  2001-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09031936.01.00086201PMID 11491179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sodium channel blockers and uridine triphosphate: effects on nasal potential difference in cystic fibrosis mice.

  2000cited by this paper
• Pharmacogenetics of asthma.

  2000cited by this paper
• A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.

  2000cited by this paper
• Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR.

  2000cited by this paper
• Mechanism and Cellular Applications of a Green Fluorescent Protein-based Halide Sensor*

  2000cited by this paper
• Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia.

  2000cited by this paper
• CFTR is a conductance regulator as well as a chloride channel.

  1999cited by this paper
• The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis.

  1999cited by this paper
• Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis.

  1998cited by this paper
• Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.

  1998cited by this paper
• Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel

  1998cited by this paper
• A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.

  1998cited by this paper
• 8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator.

  1997cited by this paper
• In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium.

  1997cited by this paper
• In vivo activation of CFTR-dependent chloride transport in murine airway epithelium by CNP.

  1997cited by this paper
• C-type natriuretic peptide increases chloride permeability in normal and cystic fibrosis airway cells.

  1997influential reference
• Regulation of guanosine 3′:5′‐cyclic monophosphate in ovine tracheal epithelial cells

  1997cited by this paper
• Direct action of genistein on CFTR

  1997cited by this paper
• Genistein potentiates wild-type and delta F508-CFTR channel activity.

  1997cited by this paper
• Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line

  1997cited by this paper
• Disruption of monolayer integrity enables activation of a cystic fibrosis “bypass” channel in human airway epithelia

  1997cited by this paper
• In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.

  1997cited by this paper
• Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis (CF) mouse.

  1996cited by this paper
• Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

  1996cited by this paper
• Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations

  1996cited by this paper
• Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*)

  1996influential reference
• Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis.

  1996cited by this paper
• Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.

  1996cited by this paper
• Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines.

  1996cited by this paper
• Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.

  1996cited by this paper
• Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial.

  1995cited by this paper
• CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells.

  1995cited by this paper
• Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis

  1995cited by this paper
• Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression.

  1995cited by this paper
• A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation.

  1995cited by this paper
• Effects of Benzamil in Human Cystic Fibrosis Airway Epithelium

  1995cited by this paper
• CFTR as a cAMP-dependent regulator of sodium channels

  1995influential reference
• cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein.

  1995cited by this paper
• Effect of oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential difference in patients with cystic fibrosis.

  1995cited by this paper
• No added benefit from nebulized amiloride in patients with cystic fibrosis.

  1993cited by this paper
• A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells.

  1992cited by this paper
• Extracellular ATP and UTP induce chloride secretion in nasal epithelia of cystic fibrosis patients and normal subjects in vivo.

  1992influential reference
• Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease.

  1992cited by this paper
• Amiloride and Its Analogs: Unique Cation Transport Inhibitors

  1992cited by this paper
• Bioelectric properties of cystic fibrosis airways obtained at heart-lung transplantation.

  1992cited by this paper
• Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis.

  1991influential reference
• Transcellular sodium transport in cultured cystic fibrosis human nasal epithelium.

  1991cited by this paper
• Aerosolized amiloride as treatment of cystic fibrosis lung disease: a pilot study.

  1991cited by this paper
• Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.

  1991cited by this paper
• Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

  1990cited by this paper
• Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.

  1990cited by this paper
• A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.

  1990cited by this paper
• Digitalis. Mechanisms of action and clinical use.

  1988cited by this paper
• Digitalis mechanisms of action and clinical use

  1988cited by this paper
• Evidence for reduced Cl‐ and increased Na+ permeability in cystic fibrosis human primary cell cultures.

  1988cited by this paper
• Inhibitory actions of loperamide on absorptive processes in rat small intestine.

  1986cited by this paper
• Deposition, clearance, and effects of aerosolized amiloride in sheep airways.

  1986cited by this paper
• Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation.

  1986cited by this paper
• Oxygen Consumption and Ouabain Binding Sites in Cystic Fibrosis Nasal Epithelium

  1986cited by this paper
• Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis.

  1981cited by this paper
• The effects of sodium substitution and ouabain on ion transport by dog tracheal epithelium.

  1979cited by this paper

• ENaC is a host susceptibility factor to bacterial infections in cystic fibrosis context

  2025cites this paper
• Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.

  2020cites this paper
• Dual strategies to correct abnormal ion transports in cystic fibrosis using construct therapy

  2019cites this paper
• Simultaneous and Fast SPE-HPLC Analyses of Nine Anti-Hypertensive Drugs in Human Plasma

  2015cites this paper
• Vibrational spectra of 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazine-2-carboxamide: combined experimental and theoretical studies.

  2014cites this paper
• Cystic fibrosis

  2012cites this paper
• La protéine CFTR : Implication et cible thérapeutique dans la maladie osseuse chez les patients atteints de mucoviscidose.

  2012cites this paper
• The hERG K+ channel: target and antitarget strategies in drug development.

  2008cites this paper
• Mutations in CNGA3 impair trafficking or function of cone cyclic nucleotide‐gated channels, resulting in achromatopsia

  2008cites this paper
• Dominant‐negative effects of episodic ataxia type 2 mutations involve disruption of membrane trafficking of human P/Q‐type Ca2+ channels

  2008cites this paper
• Cystic fibrosis transmembrane conductance regulator (CFTR) functionality is dependent on coatomer protein I (COPI)

  2007cites this paper
• Pharmaceutical R&D in the spotlight: why is there still unmet medical need?

  2007cites this paper
• Quantum-Chemical Design of Cryptand-like Ditopic Salt Binders.

  2006cites this paper
• Looking back over 40 years and what the future holds

  2004cites this paper
• Cystic fibrosis: disease mechanisms and therapeutic targets

  2004cites this paper
• Using Small Molecules to Mediate and Influence Biomembrane Function

  2004cites this paper
• Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

  2003cites this paper
• Facilitated transport of sodium or potassium chloride across vesicle membranes using a ditopic salt-binding macrobicycle.

  2003cites this paper
• Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed protein.

  2003cites this paper
• Pharmacological Approaches to Correcting the Ion Transport Defect in Cystic Fibrosis

  2003cites this paper
• Pharmacological Rescue of Human K (cid:1) Channel Long-QT2 Mutations Human Ether-a-Go-Go–Related Gene Rescue Without Block Clinical Investigation and Reports

  2002cites this paper
• Disease genes: flattery and deception.

  2002cites this paper
• Pharmacological Rescue of Human K+ Channel Long-QT2 Mutations: Human Ether-a-Go-Go-Related Gene Rescue Without Block

  2002cites this paper
• Urogenital abnormalities in male children with cystic fibrosis

  2002cites this paper
• Synthetic membrane transporters.

  2002cites this paper